Six years separated from a rabies vaccine scandal, China’s YishengBio grabs $130M to go big in infectious diseases, cancer
In another boost to the global vaccine field, top investors in China have huddled together to inject $130 million into Beijing-based YishengBio.
Co-led by Oceanpine …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
